Meitar Law Offices acts across the full spectrum of the life sciences and healthcare sector, representing global pharmaceutical companies, medical device manufacturers, digital health and AI companies, biotech and diagnostics businesses, and healthcare investors. The team’s expertise ranges from high-value cross-border M&A and strategic partnerships, to IP protection and management, to clinical trials, product liability disputes and financing. The team also advises on privacy issues, licensing, commercial agreements, compliance, and strategic collaborations and joint ventures. Haim Gueta advises entrepreneurs, start-ups, and pharmaceutical, biotechnology and medical device companies on corporate and strategic transactions, cross-border M&A, private equity, and venture capital investments; Boaz Mizrahi advises on technology transactions and IP commercialization; and Ron Peleg heads the product liability, class actions, and mass tort litigation practice. David Shulchani was promoted to partner in January 2025.
Legal 500 Editorial commentary
Accolades
Client satisfaction: Sector knowledge
Testimonials
Collated independently by Legal 500 research team.
- ‘The practice is defined by its openness to innovation. Whether through leveraging advanced technology to streamline processes, adopting flexible billing structures to align with client needs, or fostering an inclusive and collaborative working environment, the team continually demonstrates forward-thinking adaptability.’
- ‘What sets the group apart is its ability to translate the most complex scientific developments into practical, forward-looking legal strategies that directly advance client objectives.’
- ‘Boaz Mizrahi is an anchor of excellence, whose presence elevates the entire practice. His expertise across IP, biology, and biotechnology is unmatched, and his leadership is instrumental in shaping the team’s distinctive approach.’
- ‘Boaz Mizrahi is truly in a class of his own. He is not simply excellent, he is exceptional in every dimension.’
- ‘Boaz Mizrahi combines a depth of expertise in IP law with an unparalleled grasp of biology, biotechnology, and the wider life sciences, a rare combination that makes him uniquely positioned to advise clients at the most sophisticated levels.’
- ‘This practice distinguishes itself through a rare fusion of legal excellence, scientific sophistication, and commercial acumen. The team operates at the intersection of law and cutting-edge innovation, with particular strength in IP, biotechnology, and the life sciences.’
- ‘Their client service model is built on responsiveness, clarity, and partnership, ensuring that clients feel supported not only in navigating legal complexities but also in achieving their long-term business goals.’
- ‘The team’s capabilities extend far beyond traditional legal advisory work. They combine deep technical knowledge with strategic creativity, consistently delivering solutions that protect innovation while driving commercial growth.’
- Among the outstanding professionals I have had the privilege to work with, Boaz Mizrahi is truly in a class of his own. He is not simply excellent; he is exceptional in every dimension. Boaz combines a depth of expertise in intellectual property law with an unparalleled grasp of biology, biotechnology, and the wider life sciences, a rare combination that makes him uniquely positioned to advise clients at the most sophisticated levels.
- This practice distinguishes itself through a rare fusion of legal excellence, scientific sophistication, and commercial acumen. The team operates at the intersection of law and cutting-edge innovation, with particular strength in intellectual property, biotechnology, and the life sciences. What sets the group apart is its ability to translate the most complex scientific developments into practical, forward-looking legal strategies that directly advance client objectives.
Key clients
- Pfizer
- GlaxoSmithKline Research & Development
- Integra Lifesciences
- Medivators
- MediWound
- Gamida Cell
- Access Industries
- Ayala Pharmaceuticals
- CaribouBio
- Corcept Therapeutics
- Senseera
- Alive Israel Healthtech Fund
- Neura
- Mapi Pharma
- Equashield Medical
- Varay Oncology Systems
- Oncohost
- PhenoAI
- Max Ovary 23
- Shempriz Health
Work highlights
Advised Pfizer, as co-lead investor, on CytoReason’s $80 million financing round, which also included participation from OurCrowd, NVIDIA and Thermo Fisher Scientific.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
Haim Gueta; Boaz Mizrahi; Ron Peleg
Other key lawyers
David Shulchani; Gilad Schiff; Rebecca Fisher; Daniel Colthof; Adi Blumenthal Yaari